Interestingly, Bmal1 knock-down significantly inhibited the protein level of Cx43 in the normal astrocytes or NMO astrocytes, which was neither changed by the treatment of TAT-Gap19 and DQP-1105 in normal astrocytes nor the treatment of LA or glutamate treatment in NMO astrocytes (Figure 5A). This evidence concerns the gene BMAL1 and neuromyelitis optica.